GlassScriptPhysician profile
Maria Espinoza
NPI 1518546779
$1,185.88
in general payments reported to CMS, 2019-2025
15 companies · $952 in 2025
The $952 reported for 2025 was more than what 87% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $234 · 2025: $952.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $780 · Education: $406.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $779.97 |
| Education | $405.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $255.93 | 2025 | |
| Kite Pharma, INC. | $174.23 | 2025 | Yescarta |
| Sun Pharmaceutical Industries INC. | $121.83 | 2024 | |
| Merck Sharp & Dohme LLC | $111.61 | 2024-2025 | Keytruda |
| Incyte Corporation | $101.84 | 2025 | Jakafi, Monjuvi, Zynyz |
| Sobi, INC | $99.99 | 2025 | |
| Lilly USA, LLC | $65.11 | 2025 | Jaypirca, Verzenio, Retevmo |
| Astrazeneca Pharmaceuticals LP | $49.60 | 2025 | Enhertu |
| Genentech USA, INC. | $42.20 | 2025 | Columvi, Tecentriq |
| Janssen Biotech, INC. | $34.42 | 2025 | Carvykti |
| Adc Therapeutics America, INC. | $34.17 | 2024 | |
| Celgene Corporation | $30.13 | 2025 | Reblozyl |
| Alexion Pharmaceuticals, INC. | $23.71 | 2025 | Ultomiris |
| Genzyme Corporation | $23.51 | 2024 | |
| Eisai INC. | $17.60 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Espinoza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.